drugset / Trial / NCT04146038
Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease
Phase 2
Completed
5 enrolled
Rutgers, The State University of New Jersey
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies the side effects of salsalate when added to venetoclax and decitabine or azacitidine in treating patients with acute myeloid leukemia or myelodysplasia/myeloproliferative disease that has spread to other places in the body (advanced). Drugs used in chemotherapy, such as salsalate, venetoclax, decitabine, and azacitidine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Timeline
- Start
- 2020-10-26
- Primary completion
- 2021-10-25
- Completion
- 2022-10-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Salsalate | Small molecule | — | Oral |
| Background | Azacitidine | Other / unclassified | — | Intravenous |
| Background | Decitabine | Small molecule | — | Intravenous |
| Background | Venetoclax | Small molecule | — | Oral |